Previous Article | Next Article 
Infect Immun, August 1998, p. 3682-3688, Vol. 66, No. 8
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Molecular Basis for Antigenic Variation of a
Protective Strain-Specific Antigen of Ehrlichia
risticii
Biswajit
Biswas,
Ramesh
Vemulapalli,
and
Sukanta K.
Dutta*
Virginia-Maryland Regional College of
Veterinary Medicine, University of Maryland, College Park, Maryland
20742
Received 15 December 1997/Returned for modification 16 February
1998/Accepted 19 May 1998
 |
ABSTRACT |
Ehrlichia risticii, the causative agent of Potomac
horse fever, has recently been isolated from many vaccinated horses
with typical clinical signs of the disease. The heterogeneity of the E. risticii isolates obtained from the vaccinated horses
necessitates the identification of the molecular basis of strain
variations to elucidate the vaccine failure and to aid in the
development of an efficient vaccine against this disease. As an
attempt, two major cross-reacting surface antigen genes of 50- and
85-kDa antigens, present separately in strains 25-D (isolated in 1984)
and 90-12 (isolated in 1990 from a vaccinated horse), respectively,
were cloned and sequenced. A comparative sequence analysis revealed differences and similarities between these two antigens with
strain-specific sizes (SSA). The 2.5- and 1.6-kb genes coding for the
85- and 50-kDa proteins, respectively, contained many different tandem repeats. The identical repeat motifs were more frequent in the middle
of both genes, but the numbers and positions of the repeats were
altogether different in the genes. Many of these direct repeats of both
genes had exact sequence homology and coded for the same amino acids.
The homology of the 5'- and 3'-flanking regions of the two genes was
greater than that of the regions in the central part of the genes. A
comparative analysis of the deduced amino acid sequences of these two
antigen genes indicated eight common domains, which were designated
identical domains. Although the sequence homologies of these identical
domains were the same, the positions of the domains in their respective
strains were completely different. This finding might be one of the
bases of antigenic variation between the strains. In addition, there
were a few unique regions in both antigen genes where no sequence
homology existed. These specific regions were designated unique
domains. The 50-kDa protein had two such unique domains, and the 85-kDa protein had six such unique domains. The presence of such unique domains contributed to the large size variation of these SSA. The
cross-reactivity of recombinant proteins confirmed the presence of
conserved epitopes between these two antigens. The SSA have been
determined to be apparent protective antigens of E. risticii.
 |
INTRODUCTION |
The obligate intracellular bacterium
Ehrlichia risticii is the etiologic agent of Potomac horse
fever (PHF). The disease is characterized by fever, leukopenia,
depression, anorexia, and profuse diarrhea and affects horses of all
ages, with a fatality rate as high as 20%. The mode of transmission of
this disease remains unknown.
Although PHF has been well recognized and studied for a decade, the
immune response against E. risticii infection is still not
completely understood. Specifically, the role of individual E. risticii antigens in eliciting the immune response during
infection is not well defined. In addition, the implication of strain
variations in PHF vaccine failure in horses necessitates a better
understanding of the molecular heterogeneity of major antigens. Studies
in our laboratory indicated marked phenotypic and genotypic diversity between two strains of E. risticii (24).
Heterogeneity is seen mainly in the surface antigens, as demonstrated
by serological analysis (8, 24).
To describe in more detail the antigenic heterogeneity of E. risticii strains, we began a molecular analysis of two strains, with the aims of isolating the genes of major protein immunogens and of
determining the strain-specific differences in the surface antigens.
The two E. risticii strains used were 25-D and 90-12 (24). Strain 25-D was isolated in 1984 during the original
outbreaks, and strain 90-12 was isolated in 1990 from a vaccinated
horse suffering from severe clinical PHF. A preliminary serological analysis of the component antigens of strains 25-D and 90-12 indicated that antibodies to the 85-kDa antigen of strain 90-12 cross-reacted with a 50-kDa surface antigen of strain 25-D and that the molecular masses of these antigens were specific for their corresponding strains
(24). That is, strain 90-12 does not possess the 50-kDa antigen and strain 25-D does not contain the 85-kDa antigen, indicating that although they cross-react in Western blots, these two antigens are
strain specific for their distinct molecular masses. We previously reported the ability of these antigens to stimulate a protective immune
response in a mouse model of E. risticii infection
(25).
This paper describes the molecular cloning and analysis of the 50- and
85-kDa genes, which further confirmed that the immunological variations
between the strains (in Western blots) is due to the diversity of genes
for antigens with strain-specific sizes (SSA) and demonstrated the
unique characteristics of the genes which contribute to the molecular
heterogeneity of E. risticii strains.
 |
MATERIALS AND METHODS |
E. risticii strains and cultivation.
E.
risticii 25-D and 90-12 were obtained from our laboratory stock
cultures. Both strains were cultivated in human histiocyte cell line
U937 (American Type Culture Collection) in the presence of RPMI 1640 medium (Flow Laboratories, Inc., McLean, Va.) supplemented with 4 mM
L-glutamine and 15% fetal calf serum. Infected cells were
incubated at 37°C in 5% CO2. The propagation of E. risticii in cell culture material was monitored by acridine orange
staining (4).
Purification of E. risticii and DNA extraction.
E. risticii organisms were purified by centrifugation over a
linear Renografin gradient according to procedures described previously
(5). A procedure described earlier (6) was used for the extraction of DNA from E. risticii. Briefly,
Renografin-purified organisms suspended in 50 mM Tris-25 mM
EDTA-0.9% NaCl buffer were treated with lysozyme (2 mg/ml; 37°C for
10 min), 0.5% sodium dodecyl sulfate (65°C for 30 min), and
proteinase K (400 µg/ml; Sigma Chemical Co., St. Louis, Mo.) (56°C
for 6 h). Finally, the DNA was extracted by phenol-chloroform
treatment and ethanol precipitation and then dissolved in 10 mM
Tris-0.5 mM EDTA (pH 8.0) to a concentration of 1.0 µg/ml.
Cloning of E. risticii genomes.
Fragments of the
genomic DNA of E. risticii (strain 25-D) were cloned in
vector
gt11, and a recombinant expressing the complete 50-kDa
protein antigen was identified in our laboratory (7). Additional cloning of E. risticii (strain 90-12) was
performed with vector
ZAP (Stratagene, La Jolla, Calif.). Briefly,
genomic DNA (6 µg) of strain 90-12 was restriction digested with
Sau3AI enzyme (10 U) for 1 h at 37°C. After the size
distribution was determined in a 1% agarose gel, the restricted DNA
fragments were inserted into vector
ZAP by use of conversion
adaptors as described by Stover et al. (22). Custom-made
single-stranded oligonucleotides (Oligos ET Inc., Wilsonville, Oreg.)
of different lengths, when mixed in equimolar quantities, formed duplex
adaptors of three different lengths, so that gene fusions at all three
reading frames were possible. The conversion adaptors carried an
EcoRI cohesive end at one terminus for ligation to the
ZAP arms and a restriction enzyme-specified cohesive end at the
opposite terminus for ligation to restriction DNA fragments. The
restricted DNA fragments were ligated to the conversion adaptors with
6 U of T4 DNA ligase at 15°C for 6 h. After completion of the
ligation reaction, the enzyme was heat inactivated at 70°C for 10 min. The adaptor-modified insert DNA was phosphorylated with 10 U of T4
polynucleotide kinase at 37°C for 30 min, followed by the removal of
excess adaptors by spin-column chromatography with a Sephacryl S-400
matrix (Promega Corp., Madison, Wis.). Finally, dephosphorylated,
adaptor-modified insert DNA was ligated to EcoRI-digested
and dephosphorylated vector
ZAP DNA (Stratagene) with 4 Weiss U of
T4 DNA ligase at 15°C for 6 h. The ligation mixture was packaged
in a packaging mix (Gigapack II Gold; Stratagene) at 22°C for 2 h.
Immunoscreening of recombinants for antigen expression.
The
recombinants were screened by a previously described procedure
(7) with E. risticii 90-12 antisera (rabbit and
mouse) absorbed with lysates of Escherichia coli XL1-Blue
and
ZAP phage (7). The antigen-positive recombinants were
purified by single-plaque isolation and stored in 0.1 M NaCl-10 mM
Tris (pH 7.9)-10 mM MgSO4.
Western immunoblotting and identification of recombinant
antigens.
Western blotting was performed according to a procedure
described previously (6) with mouse antisera collected at 3 weeks postinfection. The identification of recombinant antigens was performed by Western blotting with specific recombinant clone-specific antibodies prepared by eluting the absorbed rabbit and mouse
anti-E. risticii 90-12 antibodies from a nitrocellulose
membrane containing the recombinant
ZAP phages expressing the
E. risticii antigens according to a previously described
procedure (6, 7, 17).
Recombinant DNA procedures.
The E. risticii
antigens were expressed by several recombinant
ZAP phages. In vivo
excision of the pBluescript SK(
) phagemids from these
ZAP
recombinant phages was done according to the instructions of the
manufacturer (Stratagene). All restriction enzymes, T4 DNA ligase, and
calf intestinal alkaline phosphatase were obtained from New England
BioLabs (Beverly, Mass.) and used according to the instructions of the
manufacturer. Phagemid DNA was prepared for PCR, sequencing, and other
recombinant procedures by a modification of the procedure of Birnboim
and Doly (2). PCR-amplified products were cloned into vector
pCRII (Invitrogen). PCR mixtures and cycles were set up according to a
procedure described earlier (3).
The recombinant phagemid and plasmid DNAs were transformed into their
appropriate competent cells by electroporation or heat shock according
to manufacturers' (Bio-Rad and Invitrogen) instructions.
All preparative and nonpreparative agarose (Bio-Rad) gel
electrophoresis procedures were performed with Tris-acetate buffer, and
the DNA was visualized with ethidium bromide (Sigma). Cloned inserts
were separated from recombinant plasmid or phagemid DNAs by appropriate
restriction enzyme digestion. The insert bands of recombinants, as
ascertained by electrophoresis, were excised and processed for
purification of DNA with GenecleanII (Bio 101, Inc., La Jolla, Calif.)
silica matrix.
DNA sequence determination and analysis.
Denatured
double-stranded DNA sequencing was accomplished by a modification of
the dideoxy chain termination method of Sanger et al. (15,
21) with the Sequenase version 2.0 kit (Amersham).
The nucleotide and deduced amino acid sequences were analyzed with IBI
Pustell (IBI Limited, Cambridge, England) and PepPlot software. PepPlot
was written by Michael Gribskov and John Deverenux of the Genetics
Computer Group and is available through the National Institutes of
Health, Bethesda, Md.
Expression of cloned E. risticii antigens.
All
of the recombinant antigens were expressed in E. coli JM109
cells and purified under denaturing conditions according to the
manufacturer's (Invitrogen) pRSET-ABC expression system protocol.
Nucleotide sequence accession numbers.
The sequences of the
50- and 85-kDa antigen genes were deposited in the GenBank data library
under accession numbers AF059672 and AF059673, respectively.
 |
RESULTS |
Cloning and sequencing of the 50- and 85-kDa-antigen
genes.
A single recombinant clone, designated pB50-6,
expressing the 50-kDa antigen was identified from the
gt11 library
of strain 25-D. Two different recombinant clones, designated pB85-11
and pB85-17, expressing the 85-kDa antigen were isolated from the
ZAP library of strain 90-12. Initial Western blot analysis of these
clones revealed that the 85-kDa antigen was expressed in a fusion
with the Lac-Z
peptide (data not shown). Further, clone-specific antibodies of either recombinant antigen reacted with the 50- and
85-kDa proteins of strains 25-D and 90-12, respectively (data not
shown). Also, in Southern blot analysis, probes made from the inserts
of the recombinant clones of either antigen hybridized with genomic DNA
of both strains (24). Based on this antigenic and genomic
relatedness and because of the different molecular sizes of the
antigens, the 50- and 85-kDa proteins were designated SSA homologs for
strains 25-D and 90-12, respectively.
The 3.9-kb insert of clone pB50-6 was digested with various restriction
enzymes, and the resulting smaller fragments were subcloned in
pBluescript SK(+). By sequencing of these fragments, the complete
nucleotide sequences of the 50-kDa-antigen gene and its 5'- and
3'-flanking regions were obtained.
Clones pB85-11 and pB85-17 contained inserts of 4.5 and 1.1 kb,
respectively. These two clones contained overlapping regions, and
together they contained 845 bp of the 85-kDa-antigen gene sequence
(Fig. 1). Further analysis of clone
pB85-17 revealed partial sequence homology with the
50-kDa-antigen gene. Thus, the remaining 165 bp of the 5' region
of the gene was separately cloned by PCR from strain 90-12 genomic DNA with primers 50-C (5' GAA TGT TCA GCT TTC CGG
3') and 50-D (5' AGC TGT ATC GTT CGT GAG 3'). The
1.5-kb amplified fragment was cloned in vector pCRII, designated
pCR85-3, and sequenced (Fig. 1).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 1.
Composite profile of three overlapping clones of the
85-kDa-antigen gene and their positions with respect to the gene. The
two overlapping clones, pB85-17 and pB85-11, were identified from the
genomic library of strain 90-12. The insert, pCR85-3, was amplified
directly from the genomic DNA of strain 90-12 by use of two specific
primers, 50-C and 50-D. The sequence information of primer 50-C was
obtained from the upstream region of the 50-kDa-antigen gene sequence,
whereas that of primer 50-D was obtained from the sequence of clone
pB85-17.
|
|
Nucleotide sequence analysis.
Analysis of the nucleotide
sequence of the 50-kDa-antigen gene revealed a 1,617-bp-long open
reading frame (ORF) and 896-bp upstream and 146-bp downstream noncoding
regions (Fig. 2). The complete ORF was
capable of coding for a 59.83-kDa protein consisting of 539 amino
acids. The upstream region contained nearly perfect prokaryotic
promoter sequences (13, 26). A purine-rich region present
upstream of the start codon was identified as a potential ribosome
binding site (Fig. 2).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
Nucleotide sequence of the 50-kDa-antigen gene and
flanking regions and deduced amino acid sequence. Putative 10, 35,
and ribosome binding site regions are underlined, and the putative
start of transcription is denoted with +1. Regions of dyad symmetry and
adjacent thymine-rich regions are underlined.
|
|
The ORF of the 85-kDa-antigen gene was 2,547 bp long and capable of
coding for a protein of 94.33 kDa consisting 849 amino acids. The 5'-
and 3'-flanking regions contained regulatory elements similar to those
described for the 50-kDa-antigen gene. The most important
finding of the nucleotide analyses was the presence of several direct
repeats in both genes. These repeats were more frequent in the middle
of the genes, and many of these repeats were identical in both genes.
All of the identical repeats coded for the same amino acids, but the
positions and frequencies of these repeats were different in both
genes. Also, the lengths and sequences of the direct repeats varied
between both genes. The composite profiles of the repeats and their
abundances in the 50- and 85-kDa-antigen gene sequences are presented
in Fig. 3. Because of the abundance of
11-nucleotide-long repeats in both genes, these repeats were further
analyzed for their sequence composition (Table
1).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Bar diagrams of direct repeats of 50- and 85-kDa-antigen
gene sequences. The repeats are categorized according to their
base-pair size, denoted by the numbers (55 to 10) placed under the
bars. Each bar was then subdivided according to the sequence homologies
of the repeats, as denoted by the block(s) in each bar.
|
|
Analyses of deduced amino acid sequences of SSA homologs.
Analyses of the deduced amino acid sequences of the 50- and 85-kDa
antigens indicated considerable homology between these two SSA
homologs. The identical repeats of their two genes code for the same
amino acids, indirectly indicating the conserved regions of these two
antigens. Substitutions or additions of one or several contiguous amino
acid residues were identified throughout the molecules, but the
significant homology in the amino acid sequences of the 50- and 85-kDa
antigens was very pronounced in certain regions. These specific areas
were designated identical domains (ID). The most interesting feature of
these ID was their unique distribution in the amino acid sequences of
individual antigens. The domains were positioned one after
another (ID I to ID VIII) in the 50-kDa antigen, whereas the
positioning of the same domains was totally different in the
85-kDa antigen (Fig. 4). In these ID, the
similarities in the amino acid sequences between the two antigens
varied from more than 94% to less than 79%.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
Schematic diagram of the diversity and similarity of the
50- and 85-kDa antigens. The numbers at the top show ID. The homology
in the amino acid sequences for the corresponding ID regions of the
tested antigens varied from more than 94% to less than 79%. The
unmarked areas indicate no homology between the two antigens.
|
|
ID I is the largest identical domain, consisting of 129 amino acids. In
ID I the amino acid sequences of the 50- and 85-kDa antigens are
very similar, and the estimated homology is 89.15% (87.08% in
nucleotide sequence), with 14 amino acid conversions. The position of
this particular domain is the same in the primary structures of both
antigens. ID II consists of 51 amino acids. In a comparison of SSA
homologs, this particular domain is found further downstream in the
85-kDa antigen. The estimated homology is 88.24% (89.54% in
nucleotide sequence), with six amino acid conversions, between the 50- and 85-kDa antigens. ID III consists of 42 amino acids. The estimated
homology in amino acid sequence is 92.85% (92.06% in nucleotide
sequence), with three amino acid conversions. This particular domain is
also found further downstream in the 85-kDa antigen than in the 50-kDa
antigen. ID IV consists of 21 amino acids. The estimated homology in
amino acid sequence is 90.48% (85.71% in nucleotide sequence), with
two amino acid conversions. With respect to the 50-kDa antigen, this
particular domain is found further upstream in the 85-kDa antigen. ID V
consists of 39 amino acids. Among all the domains, this domain has the lowest homology, 79.49% (80.34% in nucleotide sequence), in SSA homologs. This domain is found further upstream in the 85-kDa antigen
than in the 50-kDa antigen. ID VI has the highest homology, 94.55% (93.82% in nucleotide sequence), between the two
antigens. Similarly, ID VII and ID VIII possess high homology. ID VII
has 92.11% homology (85.08% in nucleotide sequence) and ID VIII has 94.12% homology (96.73% in nucleotide sequence) in their respective areas of the SSA homologs.
By comparison of the positions of all the ID in SSA homologs (Fig. 4),
it is clear that six domains out of eight are changed with respect to
their positions in these antigens. The domains are further apart from
each other in the 85-kDa antigen than in the 50-kDa antigen, and the
gaps are filled with unique sequences. This observation indicates the
presence of six major unique domains in the 85-kDa antigen and two
unique domains in the 50-kDa antigen.
Hydropathy analysis showed that the SSA of both strains have
alternative hydrophilic and hydrophobic motifs, which are
characteristic of transmembrane proteins (data not shown). The largest
hydrophobic stretch belonged to ID I and formed the hydrophobic core
region of the predicted signal peptide.
Characteristics of recombinant antigens.
The complete
ORFs of the 50- and 85-kDa antigens were constructed by PCR and
cloned in the pRSET-C expression vector (Invitrogen). The complete 50- and 85-kDa-antigen genes were amplified separately from the genomic
DNAs of the original and variant strains of E. risticii by
use of two modified primers, which created BamHI and EcoRI sites at the extreme 5' and 3' ends of the genes,
respectively. After double digestion with BamHI and
EcoRI, amplified genes were cloned separately in the
multiple cloning region of the pRSET-C expression vector. Sequence
analyses of these recombinant inserts confirmed the correct
amplification of the SSA genes directly from their respective strains.
The identities of the expressed proteins were established as the 50- and 85-kDa antigens by the reactivities of E. risticii
(strains 25-D and 90-12) polyclonal antisera and the 85-kDa
clone-specific antibody (Fig. 5). Both the 50- and the 85-kDa antigens migrated anomalously during
electrophoresis and appeared to be 9.0 kDa smaller than the predicted
sizes.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of recombinant-expressed proteins
of the 50- and 85-kDa-antigen genes. Lanes 1 contain the antigens from
E. risticii 25-D, and lanes 2 contain the antigens from
E. risticii 90-12. Lanes 3 and 4 contain E. coli-expressed recombinant 85- and 50-kDa fusion proteins,
respectively. (A) Blot reacted with sera from strain 90-12-infected
mice. The asterisk in lane 1 represents the location of the 50-kDa
antigen. This antigen is not distinguishable as a separate band, as it
overlaps with the 51-kDa antigen band. The single asterisk in lane 2 represents the location of the 85-kDa antigen band, and double
asterisks represent the location of the 51-kDa antigen band. The
changes in the sizes of the recombinant 85- and 50-kDa proteins (lanes
3 and 4, respectively) are in close agreement with the expected fusion
product of the pRSET-ABC expression system, which adds a 3.5-kDa
protein mass to its fusion products. (B) Blot reacted with recombinant
85-kDa clone-specific antibody from strain 90-12. The recombinant
85-kDa clone-specific antibody recognized only the 50-kDa antigen in
strain 25-D (lane 1) and only the 85-kDa antigen in strain 90-12 (lane
2). Numbers at right are molecular masses in kilodaltons.
|
|
 |
DISCUSSION |
The existence of antigenic variation among field isolates of
E. risticii has been well demonstrated (8, 9).
This antigenic heterogeneity, along with the poor efficacies of present
vaccines, has been implicated in PHF vaccine failure (9).
An effective vaccine against E. risticii must elicit a
protective immune response against all the strains present in the
field. This situation requires identifying and characterizing the
antigens of E. risticii that are involved in stimulating
protective immunity as well as in contributing to the antigenic
variation. Previously, we reported the major pathogenic, immunogenic,
and molecular differences between E. risticii 25-D and 90-12 (24). One important antigenic difference was the presence of
an 85-kDa antigen in strain 90-12 and its cross-reactive homolog,
a 50-kDa antigen, in strain 25-D. We also demonstrated that these
two antigens could stimulate protective immune responses in a murine
model of PHF (25). The present study revealed the
molecular basis of the size and antigenic variations of the two
antigens. The presence of variable numbers of tandem repeat sequences
accounts for the large size variation between the two antigens. This
type of size difference in immunological cross-reactive antigens has
been observed among isolates of other rickettsial and ehrlichial
organisms (10, 12, 19, 20, 23, 28). However, the E. risticii SSA appear to be unique in the number and complexity of
the repeats units.
The lengths of the repeats in the 50- and 85-kDa-antigen genes are
comparatively shorter than those of the repeats in the gene for the
120-kDa immunodominant protein of E. chaffeensis (28) and the rompA gene
of Rickettsia rickettsii, R. conorii, and
R. akari (10), but the number of repeats is
higher in E. risticii than in any other
Rickettsia or Ehrlichia species. The most
abundant repeats in the 50- and 85-kDa-antigen gene sequences are 11 nucleotides long, whereas in the 120-kDa-protein and rompA genes the average length of the repeats is between 200 and 250 nucleotides. Repeat structures such as those in SSA homologs are thought to develop by unequal homologous recombination (11, 14,
27), slip strand mispairing during replication (16, 18), or both.
In the SSA genes, the homology of the 5'- and 3'-flanking regions is
greater than that of the regions encoding the two variant proteins. The
degree of homology of the flanking regions suggests that
transcriptional regulation of the SSA genes is similar among the
strains.
Southern blot hybridization of restriction endonuclease
(EcoRI and HindIII) digests of the genomic
DNAs from these two strains with a cloned probe for the 85-kDa antigen
showed only one hybridizable restriction fragment (24). This
result suggests that the SSA homolog genes reside in a similar genomic
context in each antigenic variant and that only one SSA allele is
represented in each strain of E. risticii. Further research
also indicates that the sizes of the SSA appear to be very stable
during passage through animal or in vitro cell cultures. In our
studies, the sizes of these antigens remained unchanged for 100 cell
culture or three horse and mouse passages (unpublished data). This
result indicates that the observed size variations are not caused by
the laboratory manipulation of E. risticii. Recently, we
demonstrated size variations of SSA from several isolates of E. risticii obtained from typical cases of PHF in the field
(9). To understand the complete evolution of SSA genes, it
is necessary to know at what stage of the E. risticii life
cycle the events leading to size and sequence variations of SSA occur;
one possible location could be in an as-yet-unidentified transmission
vector.
A 125I surface labeling experiment determined that the
50-kDa protein of strain 25-D is an apparent surface antigen
(6). The immunological cross-reactivity and sequence
homology proved that the 85-kDa protein of strain 90-12 is the homolog
of the 50-kDa protein; thus, this particular protein also is present on
the surface of strain 90-12. Comparative analyses of deduced amino acid
sequences of SSA homologs from the two different strains of E. risticii revealed the presence of eight major ID in both strains,
but the positions of the respective domains in comparison to each other
were completely different in each strain. This finding might be a
source of antigenic variation because some of the exposed epitopes in
one of the proteins could have become buried in the membrane or
otherwise become inaccessible in the other protein and vice versa. It
is also possible that the exposed epitopes of these two proteins are
strain specific and that their common determinants are normally buried
in the membrane. Moreover, the presence of considerable amounts of new
sequences in the 85-kDa-antigen gene increase the chance of the
appearance of different epitopes on the surface of strain 90-12. Finally, the presence of point mutations in each ID should also be
considered a possible source of antigenic variation, but this variation
may not be caused solely by the accumulation of point mutations.
Possibly the combination of point mutations and recombinational
processes is responsible for the antigenic variation.
Analyses of the amino acid compositions and estimation of the
isoelectric points (6.45 for the 50-kDa antigen and 6.33 for the 85-kDa
antigen) of these two proteins indicated that they were almost
identical in these aspects. Although one of the interesting features is
the increase in acidic and basic residues (equal amounts) in the 85-kDa
antigen amino acid composition, this fact does not increase the total
charge on the surface of the molecule but produces more hydrophilic
regions which can be exposed as outer membrane domains. Thus, the
possibility of generating more epitopes on the surface is much higher
for strain 90-12 than for strain 25-D. The migration patterns of the
two expressed proteins in sodium dodecyl sulfate gels matched those of
their respective native proteins, yet the sequential sizes of both of
the proteins differed by 9.0 kDa from the observed sizes in the gels.
This type of anonymous migration is a common feature of proteins which
have tandem repeats in their gene sequences (1).
The possibility of using the nucleotide sequences of the 50- and
85-kDa-antigen genes as a starting point for a recombinant or subunit
vaccine is attractive. Previously it was observed that in
cross-protection studies, mice immunized with strain 90-12 were
completely protected from a challenge infection with strain 25-D, but
mice immunized with strain 25-D were partially protected against
challenge with strain 90-12 (24). A similar but more pronounced result was obtained when the purified recombinant 50- and
85-kDa antigens were used for immunization (25). Mice
immunized with the 50-kDa antigen were protected against homologous
strain 25-D but not against heterologous strain 90-12, whereas mice
immunized with the 85-kDa antigen were protected against both strains.
This difference in immunoprotection correlates with the molecular
difference between the antigens of the respective strains. The
cumulative results of all of these experiments suggest that variation
in the surface antigens of E. risticii, such as the 50- and
85-kDa antigens, may contribute to vaccine failure. However, before use as a recombinant vaccine, it is necessary to confirm that the above
proteins or their homologs in different strains are indeed highly
protective immunogens.
Additionally, with the nucleotide sequences of the SSA genes, a PCR
assay can be developed to quickly identify strain differences among
field isolates of E. risticii. However, characterization of
the highly unusual repetitive structure of the 50- and 85-kDa antigens
of E. risticii strains should be pursued for a better understanding of the role of these proteins in the
Ehrlichia-host interaction.
 |
FOOTNOTES |
*
Corresponding author. Mailing address:
Virginia-Maryland Regional College of Veterinary Medicine, University
of Maryland, 8075 Greenmead Dr., College Park, MD 20742-3711. Phone:
(301) 935-6083. Fax: (301) 935-6079. E-mail:
sd31{at}umail.umd.edu.
Present address: Center for Molecular Medicine and Infectious
Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061.
Editor: R. N. Moore
 |
REFERENCES |
| 1.
|
Anderson, B. E.,
G. A. McDonald,
D. C. Jones, and R. L. Regnery.
1990.
A protective protein antigen of Rickettsia rickettsii has tandemly repeated, near-identical sequences.
Infect. Immun.
58:2760-2769[Abstract/Free Full Text].
|
| 2.
|
Birnboim, H. C., and J. Doly.
1979.
A rapid alkaline extraction procedure for screening recombinant plasmid DNA.
Nucleic Acids Res.
7:1513-1523[Abstract/Free Full Text].
|
| 3.
|
Biswas, B.,
D. Mukherjee,
B. L. Mattingly-Napier, and S. K. Dutta.
1991.
Diagnostic application of polymerase chain reaction for detection of Ehrlichia risticii in equine monocytic ehrlichiosis (Potomac horse fever).
J. Clin. Microbiol.
29:2228-2233[Abstract/Free Full Text].
|
| 4.
|
Dutta, S. K.,
A. C. Myrup,
R. M. Rice,
M. G. Roble, and R. C. Hammond.
1985.
Experimental reproduction of Potomac horse fever in horses with a newly isolated Ehrlichia organism.
J. Clin. Microbiol.
22:265-269[Abstract/Free Full Text].
|
| 5.
|
Dutta, S. K.,
R. M. Rice,
T. D. Hughes,
P. K. Savage, and A. C. Myrup.
1987.
Detection of serum antibodies against Ehrlichia risticii in Potomac horse fever by enzyme-linked-immunosorbent assay.
Vet. Immunol. Immunopathol.
14:85-92[Medline].
|
| 6.
|
Dutta, S. K.,
B. Shankarappa,
S. R. Thaker, and B. L. Mattingly-Napier.
1990.
DNA restriction endonuclease cleavage pattern and protein antigenic profile of Ehrlichia risticii.
Vet. Microbiol.
25:29-38[Medline].
|
| 7.
|
Dutta, S. K.,
B. Shankarappa, and B. L. Mattingly-Napier.
1991.
Molecular cloning and analysis of recombinant major antigen of Ehrlichia risticii.
Infect. Immun.
59:1162-1169[Abstract/Free Full Text].
|
| 8.
|
Dutta, S. K.,
B. Shankarappa, and B. Mattingly-Napier.
1991.
Antigenic analysis of Ehrlichia risticii isolates, p. 61-65.
In
W. Plowright, P. D. Rossdale, and J. F. Wade (ed.), Equine infectious diseases, vol. VI. R&W Publication Ltd., Cambridge, England.
|
| 9.
|
Dutta, S. K.,
R. Vemulapalli, and B. Biswas.
1998.
Association of deficiency in vaccine antibody response and heterogeneity of Ehrlichia risticii strains with vaccine failure in Potomac horse fever.
J. Clin. Microbiol.
36:506-512[Abstract/Free Full Text].
|
| 10.
|
Gilmore, R. D.
1993.
Comparison of the romp A gene repeat regions of Rickettsiae reveals species-specific arrangement of individual repeating units.
Gene
125:97-102[Medline].
|
| 11.
|
Haas, R., and T. F. Meyer.
1986.
The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion.
Cell
44:107-115[Medline].
|
| 12.
|
Hanson, B.
1985.
Identification and partial characterization of Rickettsia tsutsugamushi major protein immunogens.
Infect. Immun.
50:603-609[Abstract/Free Full Text].
|
| 13.
|
Hawley, D. K., and W. R. McClure.
1983.
Compilation and analysis of Escherichia coli promoter DNA sequences.
Nucleic Acids Res.
11:2237-2255[Abstract/Free Full Text].
|
| 14.
|
Hollingshead, S. K.,
V. A. Fischetti, and J. R. Scott.
1987.
Size variation in group A streptococcal M protein is generated by homologous recombination between intragenic repeats.
Mol. Gen. Genet.
207:196-203[Medline].
|
| 15.
|
Kraft, R.,
J. Tardiff,
K. S. Krauter, and L. A. Leinwand.
1988.
Using mini-prep plasmid DNA for sequencing double stranded templates with SequenaseTM.
BioTechniques
6:544-546[Medline].
|
| 16.
|
Levinson, G., and G. A. Gutman.
1987.
Slipped-strand mispairing: a major mechanism for DNA sequence evolution.
Mol. Biol. Evol.
4:203-221[Abstract].
|
| 17.
|
Lyon, J. A.,
R. H. Geller,
J. G. Haynes,
J. G. Chuley, and J. L. Weber.
1986.
Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene.
Proc. Natl. Acad. Sci. USA
83:2989-2993[Abstract/Free Full Text].
|
| 18.
|
Murphy, G. L.,
T. D. Connell,
D. S. Barritt,
M. Koomey, and J. G. Cannon.
1989.
Phase variation of gonococcal protein II: regulation of the gene expression by slipped-strand mispairing of a repetitive DNA sequence.
Cell
56:539-547[Medline].
|
| 19.
|
Oaks, E. V.,
C. K. Stover, and R. M. Rice.
1987.
Molecular cloning and expression of Rickettsia tsutsugamushi genes for two major protein antigens in Escherichia coli.
Infect. Immun.
55:1156-1157[Abstract/Free Full Text].
|
| 20.
|
Oaks, E. V.,
R. M. Rice,
D. J. Kelly, and C. K. Stover.
1989.
Antigenic and genetic relatedness of eight Rickettsia tsutsugamushi antigens.
Infect. Immun.
57:3116-3122[Abstract/Free Full Text].
|
| 21.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 22.
|
Stover, C. K.,
M. H. Vodkin, and E. V. Oaks.
1987.
Use of conversion adaptors to clone antigen genes in gt11.
Anal. Biochem.
163:398-407[Medline].
|
| 23.
|
Stover, C. K.,
D. P. Marana,
J. M. Carter,
B. A. Roe,
E. Mardis, and E. V. Oaks.
1990.
The 56-kilodalton major protein antigen of Rickettsia tsutsugamushi: molecular cloning and sequence analysis of the sta56 gene and precise identification of a strain-specific epitope.
Infect. Immun.
58:2076-2084[Abstract/Free Full Text].
|
| 24.
|
Vemulapalli, R.,
B. Biswas, and S. K. Dutta.
1995.
Pathogenic, immunogenic, and molecular differences between two Ehrlichia risticii strains.
J. Clin. Microbiol.
33:2987-2993[Abstract].
|
| 25.
|
Vemulapalli, R.,
B. Biswas, and S. K. Dutta.
1998.
Studies with recombinant proteins of Ehrlichia risticii; identification of strain specific antigen as a protective antigen.
Vet. Parasitol.
76:189-202[Medline].
|
| 26.
|
von Hipple, P. H.,
W. A. Ress,
K. Rippe, and K. S. Wilson.
1996.
Specificity mechanisms in the control of transcription.
Biophys. Chem.
59:231-246[Medline].
|
| 27.
|
Williams, R. O.,
J. R. Young, and P. A. O. Majiwa.
1982.
Genomic environment of T. brucei VSG genes: presence of a minichromosome.
Nature (London)
299:417-421[Medline].
|
| 28.
|
Yu, X. J.,
P. Crocquet-Valdes, and D. H. Walker.
1997.
Cloning and sequencing of the gene for a 120-kDa immunodominant protein of Ehrlichia chaffeensis.
Gene
184:149-154[Medline].
|
Infect Immun, August 1998, p. 3682-3688, Vol. 66, No. 8
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gilmore, R. D. Jr., Bellville, T. M., Sviat, S. L., Frace, M.
(2005). The Bartonella vinsonii subsp. arupensis Immunodominant Surface Antigen BrpA Gene, Encoding a 382-Kilodalton Protein Composed of Repetitive Sequences, Is a Member of a Multigene Family Conserved among Bartonella Species. Infect. Immun.
73: 3128-3136
[Abstract]
[Full Text]
-
Martin, M. E., Caspersen, K., Dumler, J. S.
(2001). Immunopathology and Ehrlichial Propagation Are Regulated by Interferon-{{gamma}} and Interleukin-10 in a Murine Model of Human Granulocytic Ehrlichiosis. Am. J. Pathol.
158: 1881-1888
[Abstract]
[Full Text]